Piper Jaffray Says BioMarin (BMRN) Could Be Taken Out for $52-$70/Share

June 12, 2012 3:49 PM EDT Send to a Friend
Get Alerts bmrn Hot Sheet
Price: $82.36 --0%

Rating Summary:
    11 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade bmrn Now!
Join SI Premium – FREE
With shares of BioMarin (Nasdaq: BMRN) modestly higher Tuesday afternoon amid chatter GSK could be eying the company, Piper Jaffray's Ian Somaiya issued some commentary on the rumor.

Although the analyst believes a takeover of the company is unlikely until results from a key clinical trial are released during the second half of this year, Somaiya placed a potential purchase price in the range of $52-$70 per share. The analyst said he sees multiple bidders being involved.

With BioMarin shares up 1.7 percent to $36.27 at last check, Somaiya's estimate implies a premium of about 43 to 93 percent.

Piper Jaffray maintains an Overweight rating and $43 price target on shares of BioMarin.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Rumors

Related Entities

Piper Jaffray

Add Your Comment